Keith Abe

2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events

Current State of knowledge on Takotsubo Syndrome: A Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology

Universal Definition of Myocardial Infarction: Clinical Insights

Fourth Universal Definition of Myocardial Infarction (2018)

European Resuscitation Council Guidelines for Resuscitation 2010 Section 2. Adult basic life support and use of automated external defibrillators

Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) – March 2013

Antithrombotic Therapy for VTE Disease

A Meta-Analysis of Randomized Controlled Trials of the Risk of Bleeding With Apixaban Versus Vitamin K Antagonists

Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti‐FXa assays

Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban

European Resuscitation Council Guidelines for Resuscitation 2010 Section 6. Paediatric life support

Comparison of two mechanical intraosseous infusion devices: A pilot, randomized crossover trial

European Resuscitation Council Guidelines for Resuscitation 2010 Section 4. Adult advanced life support

The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity

Atherosclerosis

Idarucizumab for Dabigatran Reversal

Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy

2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate

Intraosseous access in the setting of pediatric critical care transport

Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays

Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage

Role of Orally Available Antagonists of Factor Xa in the Treatment and Prevention of Thromboembolic Disease: Focus on Rivaroxaban

Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy

Reversal of Dabigatran-induced Bleeding by Coagulation Factor Concentrates in a Rat-tail Bleeding Model and Lack of Effect on Assays of Coagulation

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

Factor Xa Inhibitors: Next-Generation Antithrombotic Agents

A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

European Resuscitation Council Guidelines for Resuscitation 2005

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons

2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

Fourth Universal Definition of Myocardial Infarction (2018)

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Evolving use of new oral anticoagulants for treatment of venous thromboembolism

Fourth universal definition of myocardial infarction (2018)

2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants

Synthesis, characterization, and biomedical assessment of novel bisimidazole–coumarin conjugates

Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases

2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes

Part 14: Pediatric Advanced Life Support

Betrixaban (PRT054021): pharmacology, Dose Selection and Clinical Studies

Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design

Prescribed drugs containing nitrogen heterocycles: an overview

Abstract 12420: Reversal of Low Molecular Weight Heparin and Fondaparinux by a Recombinant Antidote (r-Antidote, PRT064445)

Intraosseous is faster and easier than umbilical venous catheterization in newborn emergency vascular access models

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa

Animal Models of Thrombosis Help Predict the Human Therapeutic Concentration of PRT54021, a Potent Oral Factor Xa Inhibitor.